{"id":71978,"date":"2026-04-30T13:44:11","date_gmt":"2026-04-30T13:44:11","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/71978\/"},"modified":"2026-04-30T13:44:11","modified_gmt":"2026-04-30T13:44:11","slug":"2026-time100-most-influential-companies","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/71978\/","title":{"rendered":"2026 TIME100 Most Influential Companies"},"content":{"rendered":"<p data-testid=\"paragraph-element\" class=\"rich-text mb-6 font-graphik text-body-large text-black-coffee focus-visible:outline focus-visible:outline-black-coffee focus-visible:outline-2 focus-visible:outline-offset-2 focus-visible:shadow-focus-color text-left\">GLP-1 weight-loss drugs work. The problem has been getting people to take them consistently\u2014weekly self-injections and high costs have kept millions from starting or staying on treatment. Novo Nordisk offered a solution. In 2025, the FDA <a href=\"https:\/\/time.com\/collections\/time100-health-2026\/7362454\/mike-doustdar\/\" title=\"undefined\" target=\"_self\" rel=\"nofollow noopener\">approved a daily pill version of Wegovy<\/a>, making it the first oral GLP-1 medication for <a href=\"https:\/\/time.com\/7342274\/the-weight-loss-drug-wegovy-now-comes-in-a-pill\/\" title=\"undefined\" target=\"_self\" rel=\"nofollow noopener\">weight loss<\/a>. The pill is cheaper to manufacture and distribute than injections, and under an agreement between pharmaceutical companies and the White House, a month&#8217;s supply of the initial dose will <a href=\"https:\/\/time.com\/7343023\/wegovy-pill-weight-loss-drugs-novo-nordisk\/\" title=\"undefined\" target=\"_self\" rel=\"nofollow noopener\">cost<\/a> $149 for people on federal insurance plans like Medicare and Medicaid, and for those paying out of pocket. The FDA also approved Eli Lilly&#8217;s competing pill, Foundayo, in April, which could transform the medications from hard-to-access injectables into a more standard treatment for obesity worldwide.<\/p>\n","protected":false},"excerpt":{"rendered":"GLP-1 weight-loss drugs work. The problem has been getting people to take them consistently\u2014weekly self-injections and high costs&hellip;\n","protected":false},"author":2,"featured_media":71979,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[7638,6992,272,39062],"class_list":{"0":"post-71978","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-franchise","9":"tag-list","10":"tag-novo-nordisk","11":"tag-time100-companies"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116493960187613424","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/71978","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=71978"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/71978\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/71979"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=71978"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=71978"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=71978"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}